Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS
Date:7/31/2014

t are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our projected financial results and anticipated financial condition for 2014 and 2015; the anticipated availability of commercial quantities of our flavor ingredients; the anticipated timing and scope of commercial launch of products containing Senomyx's flavor ingredients, whether by our collaborators or through our direct sales program; the progress and capabilities of Senomyx's discovery and development programs generally, including without limitation our ability to identify proteins primarily involved in the perception of salt taste in humans. Risks that contribute to the uncertain nature of the forward-looking statements include: the fact that the cost to manufacture and/or formulate any of our flavor ingredients into packaged food and beverage products may be higher than anticipated, which could discourage market acceptance; we are dependent on third parties to manufacture commercial quantities of all of our flavor ingredients and we may experience delays or unanticipated costs for any such third party manufacturing; we also may encounter unexpected difficulties using any of our flavor ingredients to manufacture food or beverage products at commercial scale; Senomyx may be asked to complete additional studies to evaluate and/or monitor the safety of new flavor ingredients in order to maintain applicable regulatory approvals and/or obtain regulatory approvals outside of the United States; large companies, such as PepsiCo, are typically conservative when implementing changes to their branded products, and may not begin or expand their use of Senomyx flavor ingredients when expected or at all; S
'/>"/>
SOURCE Senomyx, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 16TH ANNUAL NEEDHAM GROWTH CONFERENCE
2. SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER FINANCIAL RESULTS
3. Senomyx Announces Management Update
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
5. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
7. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
9. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
10. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
11. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... October 20, 2014 , A ... disorders and the delivery of care has revealed changing ... worrying inequalities in the provision of healthcare services across ... commissioned by United European Gastroenterology (UEG), have been announced ... public awareness of the burden of GI disorders across ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... President and Chief Business Officer of Alseres,Pharmaceuticals, ... 2nd,Annual Therapeutic Area Partnerships in Philadelphia, PA ... an overview on Alseres Regenerative,Therapeutics program. Cethrin(R), ...
... -- WuXi PharmaTech (NYSE:,WX), China,s premier provider of ... been nominated the winner of Deloitte,Technology Fast 50 ... technology,companies in China as recognized by Deloitte Touche ... The Deloitte Technology Fast 50 China program ...
... 18 Sigma-Aldrich (Nasdaq:,SIAL) announced today the ... System. N-TER allows researchers to reproducibly,interrogate gene ... types that,have previously not been considered amenable ... lipid-based siRNA transfection reagents exhibit a number,of ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference 2WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia 2Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... AUSTIN, TexasFrom deep within the genomes of organisms as diverse ... responsible for causing human diseases such as cancer and deafness. ... fact that all life on Earth shares common ancestry, and ... yeast, for example, that humans use to make veins and ...
... for the meeting Experimental Biology 2010 the American ... Society for Biochemistry and Molecular Biology, American Society ... American Society for Pharmacology and Experimental Therapeutics are ... presented April 24-28, at the Anaheim Convention Center. ...
... The general public expects businesses outside the health ... to be involved in health in ways that ... to the Edelman Health Engagement Barometer 2010. Nearly ... that is effectively engaged in health and two-thirds (65 ...
Cached Biology News:Scientists find new genes for cancer, other diseases in plants, yeast and worms 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 3Selected highlights of the research being presented at the Experimental Biology 2010 meeting 4Global study shows 'health' joins 'green' as business strategy 2Global study shows 'health' joins 'green' as business strategy 3Global study shows 'health' joins 'green' as business strategy 4
... the research-grade spectrofluorometer with a minimum 1 ... ratio 200 or greater for the Raman ... designed to keep in mind in order ... stopped-flow, titration, or anisotropic measurements. ,The FP-6500 ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...
Biology Products: